British Heart Foundation

Milestone Pharmaceuticals to Host Investor and Analyst Webcast to Review Data from ReVeRA Phase 2 Study of Etripamil in AFib-RVR

Retrieved on: 
Tuesday, November 7, 2023
Milestone, Duke University School of Medicine, Revera, Science, Assistant, American Heart Association, MD, Atrial fibrillation, Cardiology, Clinical Cardiology, Conference, British Heart Foundation, Saint George, MBA, News, Baozou Big News Events, Webcast, University, Conference call, AHA, University of London, Patient, Pharmaceutical industry

Cardiac Electrophysiology Key Opinion Leaders joining the webcast include A. John Camm, MD, and Sean Pokorney, MD

Key Points: 
  • Cardiac Electrophysiology Key Opinion Leaders joining the webcast include A. John Camm, MD, and Sean Pokorney, MD
    Conference call and webcast on Monday, November 13, 2023 at 8:00 a.m.
  • ET
    MONTREAL and CHARLOTTE, N.C., Nov. 7, 2023 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) today announced that the Company will host a virtual investor and analyst webcast on Monday, November 13, 2023 at 8:00 a.m.
  • The webcast will focus on results from the ReVeRA Phase 2 study of investigational new drug etripamil in patients with atrial fibrillation with rapid ventricular rate (AFib-RVR), which is being presented as a Featured Science presentation at the American Heart Association (AHA) Scientific Sessions 2023.
  • To access a live or recorded webcast of the event and accompanying slides, please visit the News & Events section of Milestone's investor relations website at investors.milestonepharma.com .

British Heart Foundation Features Breakthrough Heart Attack Prevention Technology in Online News Programme for World Heart Day

Retrieved on: 
Friday, September 29, 2023
Inflammation, World Heart Federation, Heart, CT, Plaque, University, Shinobu Kokoro: Hidden Heart, BHF, Cardiovascular disease, Splenic infarction, British Heart Foundation, Research, ITN, Great Western Hospital, HIV disease progression rates, Patient, Barbara Cartland bibliography, Mortality, Coronary artery disease, Great Western Hospitals NHS Foundation Trust, Death, Disease, Medical imaging, Pharmaceutical industry

OXFORD, England, Sept. 29, 2023 /PRNewswire/ -- On World Heart Day, Caristo Diagnostics Limited, a global leader in cardiac and vascular disease diagnostics and risk prediction, confirms that its CaRi-Heart® technology has been featured as part of a British Heart Foundation (BHF) programme anchored by presenter and journalist Louise Minchin on ITN Business  (link to CaRi-Heart segment or watch the entire programme). The CaRi-Heart technology, which was developed with funding from the BHF, harnesses artificial intelligence (AI) to analyze images of the heart arteries and predict the likelihood of a heart attack – based on information that is not otherwise available using current diagnostic techniques.

Key Points: 
  • On this year's World Heart Day, the British Heart Foundation launches The Hidden Heart programme to explore hidden heart conditions, innovations in research and new treatments.
  • The programme features Caristo's CaRi-Heart technology, with insights from the technology's scientific inventor as well as a clinical user and a patient.
  • The Hidden Heart programme interviewed one of Dr. Hyde's patients, who received CaRi-Heart results twice during the last few years.
  • British Heart Foundation was one of the earliest supporters of Professor Antoniades' research to predict heart attacks years before they happen.

British Heart Foundation Features Breakthrough Heart Attack Prevention Technology in Online News Programme for World Heart Day

Retrieved on: 
Friday, September 29, 2023
Inflammation, World Heart Federation, Heart, CT, Plaque, University, Shinobu Kokoro: Hidden Heart, BHF, Cardiovascular disease, Splenic infarction, British Heart Foundation, Research, ITN, Great Western Hospital, HIV disease progression rates, Patient, Barbara Cartland bibliography, Mortality, Coronary artery disease, Great Western Hospitals NHS Foundation Trust, Death, Disease, Medical imaging, Pharmaceutical industry

OXFORD, England, Sept. 29, 2023 /PRNewswire/ -- On World Heart Day, Caristo Diagnostics Limited, a global leader in cardiac and vascular disease diagnostics and risk prediction, confirms that its CaRi-Heart® technology has been featured as part of a British Heart Foundation (BHF) programme anchored by presenter and journalist Louise Minchin on ITN Business  (link to CaRi-Heart segment or watch the entire programme). The CaRi-Heart technology, which was developed with funding from the BHF, harnesses artificial intelligence (AI) to analyze images of the heart arteries and predict the likelihood of a heart attack – based on information that is not otherwise available using current diagnostic techniques.

Key Points: 
  • On this year's World Heart Day, the British Heart Foundation launches The Hidden Heart programme to explore hidden heart conditions, innovations in research and new treatments.
  • The programme features Caristo's CaRi-Heart technology, with insights from the technology's scientific inventor as well as a clinical user and a patient.
  • The Hidden Heart programme interviewed one of Dr. Hyde's patients, who received CaRi-Heart results twice during the last few years.
  • British Heart Foundation was one of the earliest supporters of Professor Antoniades' research to predict heart attacks years before they happen.

Scottish Medicines Consortium Accepts VAZKEPA® (icosapent ethyl) to Help Reduce Cardiovascular Risk for Patients in Scotland(1)

Retrieved on: 
Monday, August 7, 2023
Knowledge, Heart, National Health Service, Myocardial infarction, MI, Hospital, Moyamoya disease, Acute coronary syndrome, Stroke, Cardiovascular disease, Splenic infarction, British Heart Foundation, Risk assessment, CVD, Glasgow Royal Infirmary, History, Healthcare Improvement Scotland, Professional corporation, Death, SMC, Molina Healthcare, Patient, ACS, Risk, LDL, Eicosapentaenoic acid, NHS, NICE, National Institute for Health and Care Excellence, Pharmaceutical industry, Nursing, Amarin, NHS Scotland

DUBLIN, Ireland and BRIDGEWATER, N.J., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announces that the Scottish Medicines Consortium (SMC) has accepted VAZKEPA® (icosapent ethyl) for reimbursement with a Patient Access Scheme* for secondary prevention in patients treated with a stable dose of statins, low-density lipoprotein (LDL) cholesterol levels >1.04mmol/L and ≤2.60mmol/L, raised fasting triglycerides (≥1.7mmol/L) and with established cardiovascular disease (CVD) defined as a history of any of the following: acute coronary syndrome (ACS) such as myocardial infarction (MI) or unstable angina needing hospitalization; coronary or other arterial revascularization procedures; coronary heart disease; ischaemic stroke; or peripheral arterial disease.1

Key Points: 
  • This represents an important step forward in the fight against CVD in Scotland,” said Professor Adrian Brady, Consultant Cardiologist at Glasgow Royal Infirmary.
  • Amarin is working with Health Boards across Scotland to secure formulary inclusion and ensure that as many patients as possible among the eligible population will have access to VAZKEPA® by the end of 2023.
  • * Patient Access Schemes are confidential pricing agreements proposed by pharmaceutical companies to enable patient access to new medicines and treatments.
  • The Patient Access Scheme Assessment Group (PASAG) reviews and advises NHSScotland on the feasibility of proposed schemes for implementation.

MedHub-AI Appoints Medical Device Industrial Expert and Cardiac Care Innovator Dr. Justin Davies as President

Retrieved on: 
Thursday, July 6, 2023
British Heart Foundation, Imperial, Doctor of Philosophy, Hypertension, TEL, Justin, Justin Davies, Pilot in command, Medical device, Pharmaceutical industry

Dr. Davies is a leading medical device entrepreneur and a pioneer of the instantaneous wave-free ratio (iFR) technique.

Key Points: 
  • Dr. Davies is a leading medical device entrepreneur and a pioneer of the instantaneous wave-free ratio (iFR) technique.
  • As MedHub continues to implement its go-to-market strategy, the inclusion of Dr. Justin Davies to the team will provide further expertise and capabilities to the company.
  • Justin has a proven track record of helping small and medium-sized companies gain a leading market position.
  • "We are thrilled to have a leading industry expert with Dr. Justin Davies' extensive medical device development expertise join our company," said Or Bruch-El, CEO of MedHub.

Caristo Diagnostics Applauds FDA Approval of Colchicine as First Anti-Inflammatory Drug for Cardiovascular Disease

Retrieved on: 
Thursday, June 22, 2023
Inflammation, Plaque, University, Myocardial infarction, MI, Stroke, Cardiovascular disease, British Heart Foundation, C-reactive protein, FAI, CCTA, Biomarker, Meta-analysis, Colchicine, Atherosclerosis, HRP, CRP, Patient, Risk, Algorithm, Tumor necrosis factor, Fat, Juan Carlos Ferrero, FDA, Regulation of tobacco by the U.S. Food and Drug Administration, Food, Pharmaceutical industry, Medical imaging

OXFORD, England, June 22, 2023 /PRNewswire/ -- Caristo Diagnostics Limited, a global leader in cardiac and vascular disease diagnostics and risk prediction, applauds the FDA's decision to approve colchicine as first anti-inflammatory drug for cardiovascular disease. Caristo reaffirms its commitment to lead innovations in CCTA based coronary inflammation detection and cardiovascular risk prediction, so every coronary inflammation patient can be identified and treated by appropriate therapy including the anti-inflammatory drug approved by the FDA.

Key Points: 
  • OXFORD, England, June 22, 2023 /PRNewswire/ -- Caristo Diagnostics Limited , a global leader in cardiac and vascular disease diagnostics and risk prediction, applauds the FDA's decision to approve colchicine as first anti-inflammatory drug for cardiovascular disease.
  • Caristo reaffirms its commitment to lead innovations in CCTA based coronary inflammation detection and cardiovascular risk prediction, so every coronary inflammation patient can be identified and treated by appropriate therapy including the anti-inflammatory drug approved by the FDA.
  • "The FDA approval of colchicine is an important tool for us to reduce coronary inflammation, a main culprit for heart attack."
  • Caristo Diagnostics was founded in 2018 to commercialize the proprietary CaRi-Heart® coronary inflammation diagnostic technology based on PVAT quantification.

Caristo Diagnostics Applauds FDA Approval of Colchicine as First Anti-Inflammatory Drug for Cardiovascular Disease

Retrieved on: 
Thursday, June 22, 2023
Inflammation, Plaque, University, Myocardial infarction, MI, Stroke, Cardiovascular disease, British Heart Foundation, C-reactive protein, FAI, CCTA, Biomarker, Meta-analysis, Colchicine, Atherosclerosis, HRP, CRP, Patient, Risk, Algorithm, Tumor necrosis factor, Fat, Juan Carlos Ferrero, FDA, Regulation of tobacco by the U.S. Food and Drug Administration, Food, Pharmaceutical industry, Medical imaging

OXFORD, England, June 22, 2023 /PRNewswire/ -- Caristo Diagnostics Limited, a global leader in cardiac and vascular disease diagnostics and risk prediction, applauds the FDA's decision to approve colchicine as first anti-inflammatory drug for cardiovascular disease. Caristo reaffirms its commitment to lead innovations in CCTA based coronary inflammation detection and cardiovascular risk prediction, so every coronary inflammation patient can be identified and treated by appropriate therapy including the anti-inflammatory drug approved by the FDA.

Key Points: 
  • OXFORD, England, June 22, 2023 /PRNewswire/ -- Caristo Diagnostics Limited , a global leader in cardiac and vascular disease diagnostics and risk prediction, applauds the FDA's decision to approve colchicine as first anti-inflammatory drug for cardiovascular disease.
  • Caristo reaffirms its commitment to lead innovations in CCTA based coronary inflammation detection and cardiovascular risk prediction, so every coronary inflammation patient can be identified and treated by appropriate therapy including the anti-inflammatory drug approved by the FDA.
  • "The FDA approval of colchicine is an important tool for us to reduce coronary inflammation, a main culprit for heart attack."
  • Caristo Diagnostics was founded in 2018 to commercialize the proprietary CaRi-Heart® coronary inflammation diagnostic technology based on PVAT quantification.

Convergint Celebrates 22nd Annual Day of Service; Colleagues Donate Time and Resources to Charitable Initiatives Across Europe

Retrieved on: 
Friday, June 9, 2023
Online Privacy, Technology, Security, Other Technology, Philanthropy, Audio, Video, Hardware, Electronic Design Automation, Fund Raising, Other Philanthropy, Global Accounting Alliance, Hospice, Culture, British Heart Foundation, Child, School, Weald, Social responsibility, Hospital, Birth control

Today, more than 9,200 Convergint colleagues across 200+ global offices have the opportunity to give back to their communities as part of the company’s 22nd annual Convergint Social Responsibility Day.

Key Points: 
  • Today, more than 9,200 Convergint colleagues across 200+ global offices have the opportunity to give back to their communities as part of the company’s 22nd annual Convergint Social Responsibility Day.
  • “Convergint Social Responsibility Day unites our global organisation – it’s inspiring to see the generosity and passion of Convergint Nation reflected around the world,” said Mike Duncan, Vice President of Global Accounts, Convergint.
  • This year, hundreds of colleagues in Europe will volunteer at schools, community centers, food banks, homeless shelters, and women’s organisations.
  • We’re proud to close our offices today so that thousands of Convergint colleagues around the world can donate their time and expertise where it’s needed most.”

United Kingdom Air Purifiers Market Report 2023: Increasing Air Pollution Drives Adoption

Retrieved on: 
Wednesday, June 7, 2023
Carbon, Heart, Allergy, UK Health Alliance on Climate Change, Asthma, Atmosphere, Periodic breathing, Smartphone, Wheeze, Sleep, Lung cancer, British Heart Foundation, Respiratory system, Brain, UK Health Security Agency, Cough, Life expectancy, USD, Public interest, Dementia, Government, Blood, Pollutant, Air pollution, Market, Nose, Death, Incidence, Nitrogen dioxide, Risk, Child, Security agency, Particulates, Filter (set theory), Copi, Growth, HEPA, City, Ageing, NHS, Health, Imperial College London, Environment Act, Forecast, Pig, Bottled water, Coal, Guardian

The United Kingdom air purifiers market is expected to witness robust growth during the forecast year owing to the increasing number of cases of airborne diseases and rapidly increasing pollution levels in several cities of the country.

Key Points: 
  • The United Kingdom air purifiers market is expected to witness robust growth during the forecast year owing to the increasing number of cases of airborne diseases and rapidly increasing pollution levels in several cities of the country.
  • An air purifier ensures the filtering of indoor air in a closed environment, which captures and delivers clean air.
  • With the rise in air pollution in different cities of the United Kingdom, the government has set up several laws to bring down the increasing air pollution level in the country.
  • In this report, the United Kingdom air purifiers market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:
    United Kingdom Air Purifier Market, by Filter Type:

VISIONARY LEADER FOR ORGANIZATIONAL AND CULTURAL CHANGE: ACADEMY OF NUTRITION AND DIETETICS NAMES WYLECIA WIGGS HARRIS, PhD, CAE, AS CHIEF EXECUTIVE OFFICER

Retrieved on: 
Monday, April 17, 2023
CAE, Food, Nutrition, American Society of Association Executives, Modern Healthcare, Education, Marketing, House of Delegates, American Health Information Management Association, American Heart Association, Dietitian, The Chicago Defender, Policy, Capella University, League, Public policy, Nursing, Research, Multimedia, Wittenberg University, Doctor of Philosophy, British Heart Foundation, Certification, Organization, American Nurses Association, League of Women Voters of California, Academy of Nutrition and Dietetics, Health, Delegate, American Heart, Woman, House, Society, Pharmaceutical industry, Management, Northwestern University

"Wylecia has impressed the Academy as an accomplished, visionary executive," said President Ellen Shanley.

Key Points: 
  • "Wylecia has impressed the Academy as an accomplished, visionary executive," said President Ellen Shanley.
  • Harris will also serve as the CEO of the Academy's Foundation— the only charitable organization devoted exclusively to promoting nutrition and dietetics.
  • The Academy and its members are committed to improving health and advancing the profession of nutrition and dietetics through research, education and advocacy.
  • Representing more than 112,000 credentialed nutrition and dietetics practitioners, the Academy of Nutrition and Dietetics is the world's largest organization of food and nutrition professionals.